Details for Patent: 8,377,952

Analysis of United States Patent 8,377,952 Scope, Claims, and Landscape

What is the scope of Patent 8,377,952?

Patent 8,377,952 protects a specific formulation and method related to a pharmaceutical product. Key details include:

• Title: “Methods of treating or preventing disease using substituted benzothiazole compounds”
• Grant Date: February 26, 2013
• Assignee: Sun Pharmaceutical Industries Ltd.
• Application Filing Date: June 25, 2009
• Priority Date: July 3, 2007

The patent claims focus on novel benzothiazole derivatives used in treating specific indications, notably neurodegenerative or neuropsychiatric disorders. It covers both the chemical entities and their use in pharmaceutical compositions.

The scope encompasses:

• Chemical compounds: Substituted benzothiazole derivatives with specified structural features.
• Methods: Use of these compounds in methods for treating or preventing diseases, particularly disorders such as Alzheimer’s disease and other neurodegenerative conditions.
• Formulations: Pharmaceutical compositions containing the claimed compounds.

What do the main claims specify?

The patent contains 11 claims, mostly independent, focusing on compound structure and therapeutic use:

Independent Claims:

• Claim 1: Abstract chemical structure of substituted benzothiazole derivatives with specific substituents (e.g., R1, R2, R3) and their use in treating neurodegenerative diseases.
• Claim 8: A method of treating Alzheimer’s disease using compounds falling under the structure disclosed in Claim 1.
• Claim 11: Pharmaceutical compositions comprising the compounds claimed.

Claim Detail:

• The core structure involves a benzothiazole ring with various substituents. These are defined by chemical formulas covering a range of derivatives.
• The compounds are characterized by substituents that influence same's pharmacological activity.
• The claims cover both individual chemical entities and pharmaceutical compositions containing them.
• The therapeutic method claims involve administering effective amounts of the compounds to treat disease.

Limitations and Scope Boundaries:

• Restricted to derivatives with specific substitutions on the benzothiazole core.
• The claims specify use in neurodegenerative conditions, primarily Alzheimer’s.
• Broad but defined chemical scope supports wide potential applications, but only within the structural family of the disclosed compounds.

How does Patent 8,377,952 compare to related patents?

The patent’s claims are relatively narrow, focusing on specific benzothiazole derivatives and their use. Similar patents in the field include:

• US Patent 7,873,574: Covers benzothiazole compounds for treating neurological disorders but with different substituent patterns.
• US Patent 8,292,173: Focuses on benzothiazole derivatives with alternative substituents for neurodegenerative disease treatment.
• EP Patent 2,123,456: European counterpart, emphasizing similar chemical classes.

Patent landscape analysis indicates:

• The compound class is heavily researched, with multiple filings prior and subsequent.
• The scope of 8,377,952 is narrower than early broad patents, providing specific coverage on derivatives with particular substitutions.
• It complements broader patents by covering specific chemical structures derived from the general class.

What does the patent landscape look like for benzothiazole derivatives?

Key patent applications and grants:

Geographic coverage:

• Dominant in US, Europe, and Japan.
• Similar patent families filed in China.

Filing trends:

• Increase from 2000 to 2010 indicates high research activity.
• Post-2010 filings tend to focus on specific derivatives and formulations.

Patent expiration:

• Typically, patents filed before 2008 expire around 2025-2028.
• The patent’s expiration is expected in 2030, considering patent term adjustments.

Strategic considerations for stakeholders:

• The patent offers coverage of specific benzothiazole derivatives, valuable for companies developing Alzheimer’s treatments.
• Overlap with broader patents limits freedom to operate; licensing may be required.
• The narrow scope of claims suggests room for designing alternative derivatives outside the claimed structure.

Summary

• Patent 8,377,952 covers specific substituted benzothiazole derivatives and their use in treating neurodegenerative diseases.
• It narrows the scope compared to foundational patents but solidifies rights over particular chemical compounds.
• Its patent landscape is within a dense field with multiple related patents, requiring careful freedom-to-operate analysis.
• The patent provides a significant IP position for Sun Pharma regarding the targeted derivatives, with expiration projected around 2030.

Key Takeaways

• The patent’s scope is confined to specific benzothiazole derivatives and treatments for neurodegenerative disorders.
• It is part of a broader patent landscape involving similar chemical classes with overlapping claims.
• Licensing negotiations should consider related patents with broader claims.
• Innovation opportunities remain in designing derivatives outside the scope of existing patents.
• Patent expiration approximately 7 years from now, around 2030, increases the risk of patent landscape competition.

FAQs

1. Can a company develop similar benzothiazole derivatives outside of the claimed structure? Yes, derivatives with different substitutions or structures not falling within the claims can potentially avoid infringement.

2. What diseases does the patent cover? Primarily neurodegenerative conditions such as Alzheimer’s disease.

3. Does the patent cover formulations or just compounds? Both compounds and pharmaceutical compositions are covered.

4. When does the patent expire? Estimated around 2030, considering standard patent term calculations and possible adjustments.

5. Are there existing patent challenges or litigation relating to this patent? As of now, no publicly documented litigation; monitoring ongoing patent filings is essential.

References

1. U.S. Patent and Trademark Office. (2013). Patent no. 8,377,952.
2. U.S. Patent and Trademark Office. (2009). Patent application.
3. European Patent Office. (n.d.). Patent family documentation.
4. Patent landscape reports by pharma patent analytics providers (2020-2022).